Tags

Type your tag names separated by a space and hit enter

Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials.
J Clin Psychiatry. 2006 Jan; 67(1):107-13.JC

Abstract

BACKGROUND

Previous research on pharmacotherapy with conventional antipsychotics has suggested that patients with affective disorders have higher rates of treatment-emergent extrapyramidal symptoms (EPS) than patients with schizophrenia. It is not known whether this differential vulnerability holds true for treatment with atypical antipsychotics such as olanzapine. The present analysis retrospectively examined olanzapine clinical trial data for incidence of treatment-emergent EPS in patients with either schizophrenia or bipolar disorder.

METHOD

Study participants were 4417 patients meeting DSM-III or DSM-IV criteria for either schizophrenia or bipolar mania participating in olanzapine clinical trials through July 31, 2001. Data were pooled across haloperidol-controlled trials and separately across placebo-controlled trials. Measures of EPS included rates of treatment-emergent EPS adverse event by type (i.e., dystonic, parkinsonian, or residual), Simpson-Angus Scale score mean change, rates of treatment-emergent parkinsonism, and rates of anticholinergic use.

RESULTS

Consistent with prior research, haloperidol-treated patients with bipolar disorder appeared to be more vulnerable to the development of EPS than those with schizophrenia. However, olanzapine-treated patients with bipolar disorder were no more likely to develop EPS than those with schizophrenia.

CONCLUSION

Results support previous research regarding conventional antipsychotics and suggest that olanzapine therapy does not increase the risk of EPS for patients with bipolar disorder.

Authors+Show Affiliations

Lilly Research Laboratories, Eli Lilly & Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. p_cavazzoni@lilly.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

16426096

Citation

Cavazzoni, Patrizia A., et al. "Comparison of Treatment-emergent Extrapyramidal Symptoms in Patients With Bipolar Mania or Schizophrenia During Olanzapine Clinical Trials." The Journal of Clinical Psychiatry, vol. 67, no. 1, 2006, pp. 107-13.
Cavazzoni PA, Berg PH, Kryzhanovskaya LA, et al. Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. J Clin Psychiatry. 2006;67(1):107-13.
Cavazzoni, P. A., Berg, P. H., Kryzhanovskaya, L. A., Briggs, S. D., Roddy, T. E., Tohen, M., & Kane, J. M. (2006). Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. The Journal of Clinical Psychiatry, 67(1), 107-13.
Cavazzoni PA, et al. Comparison of Treatment-emergent Extrapyramidal Symptoms in Patients With Bipolar Mania or Schizophrenia During Olanzapine Clinical Trials. J Clin Psychiatry. 2006;67(1):107-13. PubMed PMID: 16426096.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of treatment-emergent extrapyramidal symptoms in patients with bipolar mania or schizophrenia during olanzapine clinical trials. AU - Cavazzoni,Patrizia A, AU - Berg,Paul H, AU - Kryzhanovskaya,Ludmila A, AU - Briggs,Susan D, AU - Roddy,Tamra E, AU - Tohen,Mauricio, AU - Kane,John M, PY - 2006/1/24/pubmed PY - 2006/3/29/medline PY - 2006/1/24/entrez SP - 107 EP - 13 JF - The Journal of clinical psychiatry JO - J Clin Psychiatry VL - 67 IS - 1 N2 - BACKGROUND: Previous research on pharmacotherapy with conventional antipsychotics has suggested that patients with affective disorders have higher rates of treatment-emergent extrapyramidal symptoms (EPS) than patients with schizophrenia. It is not known whether this differential vulnerability holds true for treatment with atypical antipsychotics such as olanzapine. The present analysis retrospectively examined olanzapine clinical trial data for incidence of treatment-emergent EPS in patients with either schizophrenia or bipolar disorder. METHOD: Study participants were 4417 patients meeting DSM-III or DSM-IV criteria for either schizophrenia or bipolar mania participating in olanzapine clinical trials through July 31, 2001. Data were pooled across haloperidol-controlled trials and separately across placebo-controlled trials. Measures of EPS included rates of treatment-emergent EPS adverse event by type (i.e., dystonic, parkinsonian, or residual), Simpson-Angus Scale score mean change, rates of treatment-emergent parkinsonism, and rates of anticholinergic use. RESULTS: Consistent with prior research, haloperidol-treated patients with bipolar disorder appeared to be more vulnerable to the development of EPS than those with schizophrenia. However, olanzapine-treated patients with bipolar disorder were no more likely to develop EPS than those with schizophrenia. CONCLUSION: Results support previous research regarding conventional antipsychotics and suggest that olanzapine therapy does not increase the risk of EPS for patients with bipolar disorder. SN - 0160-6689 UR - https://www.unboundmedicine.com/medline/citation/16426096/Comparison_of_treatment_emergent_extrapyramidal_symptoms_in_patients_with_bipolar_mania_or_schizophrenia_during_olanzapine_clinical_trials_ L2 - http://www.psychiatrist.com/jcp/article/pages/2006/v67n01/v67n0116.aspx DB - PRIME DP - Unbound Medicine ER -